174 related articles for article (PubMed ID: 25819149)
1. [Thrombotic events and significance of the IPSET thrombosis risk evaluation score in essential thrombocythaemia].
Pósfai É; Marton I; Nemes A; Borbényi Z
Orv Hetil; 2015 Apr; 156(14):558-63. PubMed ID: 25819149
[TBL] [Abstract][Full Text] [Related]
2. Contribution of cardiovascular risk factors in the thrombotic complications of essential thrombocythaemia: a Hungarian single-institute retrospective analysis.
Pósfai É; Marton I; Kotosz B; Borbényi Z
Eur Rev Med Pharmacol Sci; 2015 Apr; 19(7):1258-63. PubMed ID: 25912587
[TBL] [Abstract][Full Text] [Related]
3. External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients.
Fu R; Xuan M; Lv C; Zhang L; Li H; Zhang X; Zhang D; Sun T; Xue F; Liu X; Liang H; Zhang L; Yang R
Eur J Haematol; 2014 Jun; 92(6):502-9. PubMed ID: 24460750
[TBL] [Abstract][Full Text] [Related]
4. [Essential thrombocythemia: baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients].
Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Garcia-Pallarols F; Longarón R; Ancochea À; Besses C
Med Clin (Barc); 2015 Mar; 144(6):247-53. PubMed ID: 25192581
[TBL] [Abstract][Full Text] [Related]
5. Application of prognostic score IPSET-thrombosis in patients with essential thrombocythemia of a Brazilian public service.
Navarro LM; Trufelli DC; Bonito DR; Del Giglio A; Bollmann PW
Rev Assoc Med Bras (1992); 2016 Oct; 62(7):647-651. PubMed ID: 27925044
[TBL] [Abstract][Full Text] [Related]
6. IPSET-Thrombosis Better Identifies Thrombosis-Free Survival: A Turkish Cohort.
Sevindik OG; Mersin S; Katgi A; Tunali S; Solmaz SM; Acar C; Alacacioglu I; Piskin O; Ozcan MA; Demirkan F; Undar B; Ozsan GH
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e101-4. PubMed ID: 25790738
[TBL] [Abstract][Full Text] [Related]
7. Comparison between thrombotic risk scores in essential thrombocythemia and survival implications.
Santoro M; Accurso V; Mancuso S; Carlisi M; Raso S; Tarantino G; Di Piazza F; Perez A; Russo A; Siragusa S
Hematol Oncol; 2019 Oct; 37(4):434-437. PubMed ID: 31465530
[TBL] [Abstract][Full Text] [Related]
8. Validation of thrombotic risk factors in 1381 patients with essential thrombocythaemia: A multicentre retrospective real-life study.
Stuckey R; Ianotto JC; Santoro M; Czyż A; Perez Encinas MM; Gómez-Casares MT; Noya Pereira MS; de Nałęcz AK; Gołos A; Lewandowski K; Szukalski Ł; González-Martín JM; Wróbel T; Sobas MA
Br J Haematol; 2022 Oct; 199(1):86-94. PubMed ID: 35906782
[TBL] [Abstract][Full Text] [Related]
9. Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.
Weston H; Cowell V; Grimmett K; Saal R; Jones M; Mills T; Gill D; Marlton P; Bird R; Mollee P
Intern Med J; 2011 May; 41(5):408-15. PubMed ID: 20681956
[TBL] [Abstract][Full Text] [Related]
10. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients.
Haider M; Gangat N; Lasho T; Abou Hussein AK; Elala YC; Hanson C; Tefferi A
Am J Hematol; 2016 Jun; 91(4):390-4. PubMed ID: 26799697
[TBL] [Abstract][Full Text] [Related]
11. Thrombosis and risk factors in female patients with a rare acquired thrombophilia: chronic myeloproliferative disorder - polycythaemia vera and essential thrombocythaemia.
Pósfai É; Marton I; Kiss-László Z; Kotosz B; Széll M; Borbényi Z
Eur Rev Med Pharmacol Sci; 2014; 18(24):3810-8. PubMed ID: 25555871
[TBL] [Abstract][Full Text] [Related]
12. Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia.
Hashimoto Y; Nakamae H; Tanaka T; Omura H; Horiuchi M; Yoshimura T; Takakuwa T; Mugitani A; Hirose A; Nakamae M; Koh H; Hino M
Eur J Haematol; 2018 Oct; 101(4):508-513. PubMed ID: 29971894
[TBL] [Abstract][Full Text] [Related]
13. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia.
Radaelli F; Colombi M; Calori R; Zilioli VR; Bramanti S; Iurlo A; Zanella A
Hematol Oncol; 2007 Sep; 25(3):115-20. PubMed ID: 17464935
[TBL] [Abstract][Full Text] [Related]
14. Correlation between IPSET-t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience.
Tosoni L; Liberi M; Morelli G; Zannier ME; Lazzarotto D; Filì C; Simeone E; Battaglia G; Callegari C; Fanin M; Damiani D; Fanin R; Tiribelli M
Ann Hematol; 2024 Feb; 103(2):443-448. PubMed ID: 38072850
[TBL] [Abstract][Full Text] [Related]
15. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Karadi E; Udvardy M; Egyed M
Eur J Haematol; 2017 Feb; 98(2):106-111. PubMed ID: 27557754
[TBL] [Abstract][Full Text] [Related]
16. Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis.
Guglielmelli P; Carobbio A; Rumi E; De Stefano V; Mannelli L; Mannelli F; Rotunno G; Coltro G; Betti S; Cavalloni C; Finazzi MC; Thiele J; Cazzola M; Vannucchi AM; Barbui T
Blood Cancer J; 2020 Feb; 10(2):21. PubMed ID: 32098944
[TBL] [Abstract][Full Text] [Related]
17. Risk of thrombosis in essential thrombocythemia according to three prediction models: an external validation study.
Saelue P; Thongsukhsai P
J Thromb Thrombolysis; 2023 Apr; 55(3):527-535. PubMed ID: 36652138
[TBL] [Abstract][Full Text] [Related]
18. Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin.
Kellner A; Dombi P; Illes A; Demeter J; Homor L; Ercsei I; Simon Z; Karadi E; Herczeg J; Gy Korom V; Gasztonyi Z; Szerafin L; Udvardy M; Egyed M
Eur J Haematol; 2020 Oct; 105(4):408-418. PubMed ID: 32557810
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors of thrombosis for patients with essential thrombocythaemia: A single center study.
Prajs I; Kuliczkowski K
Adv Clin Exp Med; 2017; 26(1):115-121. PubMed ID: 28397442
[TBL] [Abstract][Full Text] [Related]
20. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
